Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study

References

• Charcot JM, Joffroy A. Deux cas d’atrophie musculaire progressive: avec lesions de la substance grise et des faisceaux antérolatéraux de la moelle épiniére. Norm Pathol. 1869;2.
   Google Scholar
• Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;1:CD001447.
   Google Scholar
• Abe K, Aoki M, Tsuji S, Itoyama Y, Sobue G, Togo M, et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505–12.
   PubMed Web of Science ®Google Scholar
• FDA Approves Edaravone for Treatment of ALS | ALZFORUM; 2017. Available at: https://www.alzforum.org/news/research-news/fda-approves-edaravone-treatment-als Accessed September 18, 2018.
   Google Scholar
• Yeo CJJ, Simmons Z. Discussing edaravone with the ALS patient: an ethical framework from a U.S. perspective. Amyotroph Lateral Scler Front Degener. 2018;19:167–72.
   PubMed Web of Science ®Google Scholar
• Tang BL. Could sirtuin activities modify ALS onset and progression? Cell Mol Neurobiol. 2017;37:1147–60.
   PubMed Web of Science ®Google Scholar
• Han S, Choi J-R, Soon Shin K, Kang SJ. Resveratrol upregulated heat shock proteins and extended the survival of G93A-SOD1 mice. Brain Res. 2012;1483:112–7.
   PubMed Web of Science ®Google Scholar
• Körner S, Böselt S, Thau N, Rath KJ, Dengler R, Petri S. Differential sirtuin expression patterns in amyotrophic lateral sclerosis (ALS) postmortem tissue: neuroprotective or neurotoxic properties of sirtuins in ALS? Neurodegener Dis. 2013;11:141–52.
   PubMed Web of Science ®Google Scholar
• Dellinger RW, Santos SR, Morris M, Evans M, Alminana D, Guarente L, Marcotulli E. Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD + levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study. NPJ Aging Mech Dis. 2017;3:17.
   PubMed Web of Science ®Google Scholar
• Guo Y, Zhang L, Li F, Hu C-P, Zhang Z. Restoration of sirt1 function by pterostilbene attenuates hypoxia-reoxygenation injury in cardiomyocytes. Eur J Pharmacol. 2016;776:26–33.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Di S, Fan C, Cai L, Gao C, Jiang P, et al. SIRT1 activation by pterostilbene attenuates the skeletal muscle oxidative stress injury and mitochondrial dysfunction induced by ischemia reperfusion injury. Apoptosis Int J Program Cell Death. 2016;21:905–16.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Miller RG, Swash M, World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Mot Neuron Disord. 2000;1:293–9.
   PubMed Web of Science ®Google Scholar
• Davis C, Bryan J, Hodgson J, Murphy K. Definition of the Mediterranean Diet: a literature review. Nutrients. 2015;7:9139–53.
   PubMed Web of Science ®Google Scholar
• Kollewe K, Mauss U, Krampfl K, Petri S, Dengler R, Mohammadi B. ALSFRS-R score and its ratio: a useful predictor for ALS-progression. J Neurol Sci. 2008;275:69–73.
   PubMed Web of Science ®Google Scholar
• Wang J, Thornton JC, Kolesnik S, Pierson RN. Anthropometry in body composition. An overview. Ann N Y Acad Sci. 2000;904:317–26.
   PubMed Web of Science ®Google Scholar
• Czaplinski A, Yen AA, Appel SH. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry. 2005;77:390–2.
   Web of Science ®Google Scholar
• García-Río F, Calle M, Burgos F, Casan P, Del Campo F, Galdiz JB, Giner J. Spirometry. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). Arch Bronconeumol. 2013;49:388–401.
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Titus S, Kearney M, Yu H, Sherman A, Schoenfeld D, Hayden D. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13:1083–91.
   PubMed Web of Science ®Google Scholar
• de Carvalho M, Scotto M, Lopes A, Swash M. Quantitating progression in ALS. Neurology. 2005;64:1783–5.
   PubMed Web of Science ®Google Scholar
• Castrillo-Viguera C, Grasso DL, Simpson E, Shefner J, Cudkowicz ME. Clinical significance in the change of decline in ALSFRS-R. Amyotroph Lateral Scler. 2010;11:178–80.
   PubMed Web of Science ®Google Scholar
• Pinto S, de Carvalho M. Correlation between forced vital capacity and slow vital capacity for the assessment of respiratory involvement in amyotrophic lateral sclerosis: a prospective study. Amyotroph Lateral Scler Front Degener. 2017;18:86–91.
   PubMed Web of Science ®Google Scholar
• Guarente L. Calorie restriction and sirtuins revisited. Genes Dev. 2013;27:2072–85.
   PubMed Web of Science ®Google Scholar
• Bai P, Cantó C. The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease. Cell Metab. 2012;16:290–5.
   PubMed Web of Science ®Google Scholar
• Fang EF, et al. NAD + replenishment improves lifespan and healthspan in ataxia telangiectasia models via mitophagy and DNA repair. Cell Metab. 2016;24:566–81.
   PubMed Web of Science ®Google Scholar
• Gerdts J, Brace EJ, Sasaki Y, DiAntonio A, Milbrandt J. SARM1 activation triggers axon degeneration locally via NAD+ destruction. Science. 2015;348:453–7.
   PubMed Web of Science ®Google Scholar
• Qiu X, Brown K, Hirschey MD, Verdin E, Chen D. Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab. 2010;12:662–7.
   PubMed Web of Science ®Google Scholar
• Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature. 2005;434:113–8.
   PubMed Web of Science ®Google Scholar
• Azzolini M, La Spina M, Mattarei A, Paradisi C, Zoratti M, Biasutto L. Pharmacokinetics and tissue distribution of pterostilbene in the rat. Mol Nutr Food Res. 2014;58:2122–32.
   PubMed Web of Science ®Google Scholar
• Benlloch M, Obrador E, Valles SL, Rodriguez ML, Sirerol JA, Alcácer J. Pterostilbene decreases the antioxidant defenses of aggressive cancer cells in vivo: a physiological glucocorticoids- and Nrf2-dependent mechanism. Antioxid Redox Signal. 2016;24:974–90.
   PubMed Web of Science ®Google Scholar
• Wang B, Liu H, Yue L, Li X, Zhao L, Yang X, Wang X. Neuroprotective effects of pterostilbene against oxidative stress injury: Involvement of nuclear factor erythroid 2-related factor 2 pathway. Brain Res. 2016;1643:70–9.
   PubMed Web of Science ®Google Scholar
• Satoh T, McKercher SR, Lipton SA. Nrf2/ARE-mediated antioxidant actions of pro-electrophilic drugs. Free Radic Biol Med. 2013;65:645–57.
   PubMed Web of Science ®Google Scholar
• Wilkins HM, Kirchhof D, Manning E, Joseph JW, Linseman DA. Mitochondrial glutathione transport is a key determinant of neuronal susceptibility to oxidative and nitrosative stress. J Biol Chem. 2013;288:5091–101.
   PubMed Web of Science ®Google Scholar